#17. Daiichi-Sankyo
3-5-1 Nihombashi-honcho, Chuo-ku
Tokyo, 103-8426
Japan
Tel: (81) 3 6255 1111
Fax: (81) 3 5255 7035
www.daiichisankyo.co.jp
| Headcount |
98,000 |
| Year Established |
2005 |
| PharmA Revenues |
$6,944 |
| Total Revenues |
$8,194 |
| Net Income |
$776 |
| R&D Budget |
$1,404 |
| Drugs Approved/Launched |
| Drug |
Indication |
| urief |
dysuria |
| loxonin |
anti-inflammatory |
| Drugs in Phase IIB and Beyond |
| Drug |
Indication |
| cs-747 |
antiplatelet agent |
| colesevelam |
diabetes |
| cs-8663 |
hypertension |
| cs 917 |
diabetes |
| Early Research Projects |
| Drug |
Indication |
| cs-3030 |
anticoagulant |
| cs-9803 |
myocardial, cerebral infarction |
| da-697b |
novel anti-platelet |
| cs-7017 |
oncology |
| cs-0777 |
immunosuppressive |
| Drugs Coming Off Patent |
| Drug |
Indication |
| pravastatin |
antihyperlipidemic |
| Sales Breakdown |
| Region |
Sales |
(+/- %) |
| Japan |
$3,818 |
24% |
| Ex-Japan |
$2,562 |
7% |
Daiichi-Sankyo has not provided sales figures for its individual drugs in 2005.
